Novo Nordisk A/S
NYSE:NVO

  • LAST PRICE
    140.3700
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    141.3700/ 5
  • Ask / Lots
    141.4100/ 2
  • Open / Previous Close
    0.0000 / 140.3700
  • Day Range
    ---
  • 52 Week Range
    75.5600
    144.5000
  • Volume
    34,457

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Today

      Show headlines and story abstract

    • 1 hour ago by Dow Jones
      Companies Mentioned: NVO
      -- Improvement in time in range after smart insulin pen initiation in Austria (842-P) ------------------------------------------------------------ -- Multinational analysis of factors associated with missed bolus insulin injections using smart pen data (843-P) ------------------------------------------------------------ Obesity ------------------------------------------------------------ Wegovy(R) (once-weekly semaglutide 2.4 mg) ------------------------------------------------------------ -- CONCRETE -- characterization of patients receiving telemedicine and branded antiobesity medication for medical weight management: a retrospective analysis (1684-P) ------------------------------------------------------------ -- Clinical outcomes in patients with obesity or overweight treated with semaglutide 2.4 mg: a real-world retrospective cohort study in the United States (SCOPE 2) (1691-P) ------------------------------------------------------------ -- Modeling the Impact of Semaglutide 2.4 mg in U.S. Patients with Atherosclerotic Cardiovascular Disease and BMI >=27 kg/m2 (1981-LB) ------------------------------------------------------------ General obesity ------------------------------------------------------------ -- Patient-centered weight management clinical decision support: a proof-of-concept study (1101-P) ------------------------------------------------------------ -- Prevalence, characteristics, and clinical burden among patients with overweight or obesity and established ASCVD in a US real world setting (1692-P) ------------------------------------------------------------

  • Yesterday

Peers Headlines